Posted on 06/21/2024 9:28:11 PM PDT by ConservativeMind
An analysis of data from a randomized clinical trial for patients with stage 3 colon cancer found that those with PIK3CA mutations who took celecoxib, an anti-inflammatory drug, after surgery lived significantly longer and had longer disease-free survival compared to those without the mutation.
After primary treatment for stage 3 colon cancer, patients typically receive adjuvant chemotherapy intended to reduce the risk of the cancer returning. In a subset of these patients, the cancer returns, and those patients have few treatment options. Researchers are looking for ways to improve adjuvant therapies and stave off recurrence.
To investigate the use of celecoxib on disease-free survival in patients with stage 3 colon cancer, Meyerhardt and colleagues initiated a randomized clinical trial, the Alliance 80702 trial, in 2010. The trial enrolled 2,526 patients between 2010 and 2015. After treatment, patients were randomized to receive adjuvant chemotherapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) for three or six months with or without daily celecoxib for three years.
In this new study, Meyerhardt, Nowak, and colleagues performed comprehensive genetic sequencing called whole exome sequencing on 1200 tumor samples from patients from the Alliance 80702 trial. They found that 22% of patients had tumors with PIK3CA mutations. The patients with PIK3CA-mutated tumors who received celecoxib lived significantly longer overall compared to patients without PIK3CA mutations who received celecoxib.
In this analysis, a patient's risk of dying was reduced by about 50%, and by about 60% when excluding patients who were using low-dose aspirin for reasons not related to their cancer treatment. Disease-free survival was also improved.
"If these results are confirmed, it will be important for physicians to understand the genetics within the tumors of patients with early-stage colon cancer to determine which patients may benefit from celecoxib in addition to other standard treatments," says Meyerhardt.
(Excerpt) Read more at medicalxpress.com ...
Risk of death went down “about 60%,” with this anti-inflammatory drug.
bkmk
People are unaware that plain old aspirin, in addition to reducing the risk of MI or stroke, and relieving pain, and relieving inflammation from RA, and treating people with Afib who can't take anything else, ALSO is pretty effective at reducing the risk of colon cancer (30 percent or so).
Other COX inhibitors share these properties.
So note the hypocrisy when TPTB IMMEDIATELY condemned the off-label use of ivermectin as an anti-inflammation and anti-viral medication for severe COVID-19.
Think of aspirin when you think of respect for possible off-label uses of drugs.
Doc put me on this and a baby aspirin every day.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.